AstraZeneca’s coronavirus vaccine has been declared safe by the European Medicines Agency (EMA). According to Bloomberg, The European Medicines Agency has posted a statement regarding the matter.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
According to an EMA spokesperson, the AstraZeneca vaccine is both “safe and effective,” and its benefits far outweigh the risks. Besides, the agency does not completely dismiss the possibility that blood clots connect with the vaccination so that an investigation will continue.
Despite this, the EMA stresses that thrombosis cases are sporadic – 20 million patients received the vaccine, and only 25 patients have encountered blood clots following the vaccination.
British regulators reached a similar conclusion and recommended vaccinating with AstraZeneca. As the vaccine protects COVID-19, the potential for hospitalization and death linked to the virus outweighs the risk of potentially adverse side effects, the regulator said in a statement.
Across Europe in March, several European countries suspended vaccinations with AstraZeneca one after another. The ban was particularly enacted in France, Germany, Italy, and Spain. Reports indicate that some vaccinated patients are experiencing blood clots. Danish authorities will not reveal precisely how many thrombosis cases there have been in Denmark but say that there were “sufficient” for the decision.
The World Health Organization also recommended continuing vaccinations with AstraZeneca’s drug. According to the organization, the vaccine’s benefits outweighed the risks of using it. Several health problems associated with patients have been linked to the vaccine, but no evidence of that link has been forthcoming from WHO. The organization said that venous thromboembolism is the third most common cardiovascular disease worldwide.
Now turning to AstraZeneca yesterday’s market performance, AZN stock started trading at $49.33 and recorded an intraday high of $49.97. During Thursday’s trading session, it recorded an intraday low of $49.275. AstraZeneca PLC is one of the most active shares that witnessed a daily trading volume of more than 19.69% of its average daily work on Thursday. There were 9.79 million shares traded on Thursday.